US20100048526A1 - Pharmaceutical composition for transdermal or transmucous administration - Google Patents

Pharmaceutical composition for transdermal or transmucous administration Download PDF

Info

Publication number
US20100048526A1
US20100048526A1 US12/609,473 US60947309A US2010048526A1 US 20100048526 A1 US20100048526 A1 US 20100048526A1 US 60947309 A US60947309 A US 60947309A US 2010048526 A1 US2010048526 A1 US 2010048526A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
composition according
percentages
expressed
weight basis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/609,473
Inventor
Brigitte Taravella
Valerie Masini-Eteve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins Healthcare Luxembourg SARL
Original Assignee
Besins International Belgique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins International Belgique filed Critical Besins International Belgique
Priority to US12/609,473 priority Critical patent/US20100048526A1/en
Publication of US20100048526A1 publication Critical patent/US20100048526A1/en
Assigned to BESINS HEALTHCARE LUXEMBOURG SARL reassignment BESINS HEALTHCARE LUXEMBOURG SARL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BESINS MANUFACTURING BELGIUM
Priority to US13/353,667 priority patent/US20120122829A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Definitions

  • the present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising in particular a fatty acid as percutaneous absorption promoter, as well as a stabilizer capable of stabilizing the fatty acid in said pharmaceutical composition.
  • compositions for transdermal or transmucous administration have several advantages over oral forms: elimination of the problem of metabolism of the active substance by the liver, no gastric degradation of the active substance, possible reservoir effect with continuous release of the active principle over time. However, they may pose problems as regards the passage of the active substances through the skin.
  • transdermal or transmucous formulations may include specific molecules known as “percutaneous absorption promoters”. This name is given to any molecule that promotes the reversible diffusion of an active principle through the skin or mucous membranes, and any solubilizing agent that promotes the partition of the active principle between the vehicle and the horny layer of the epidermis or of the mucous membranes.
  • percutaneous absorption promoters This name is given to any molecule that promotes the reversible diffusion of an active principle through the skin or mucous membranes, and any solubilizing agent that promotes the partition of the active principle between the vehicle and the horny layer of the epidermis or of the mucous membranes.
  • absorption promoters commonly used in transdermal or transmucous formulations is the class of fatty acids.
  • aqueous-alcoholic compositions containing these fatty acids are not chemically stable. Specifically, on account of its “acid” function and in the presence of alcohol, the fatty acid undergoes an esterification reaction according to the laws of organic chemistry. Thus, for example, oleic acid is converted into ethyl oleate in the presence of ethanol.
  • the Applicant Company has performed extensive studies and research in order to provide a solution to this problem of stability of fatty acids in alcoholic medium, in order to obtain satisfactory stability.
  • the Applicant Company has thus found that it is possible to stabilize the fatty acid in the pharmaceutical composition by adding a buffer and/or by adding small amounts of an ester of the corresponding acid, at the time of preparation of said pharmaceutical composition.
  • the invention thus relates to a pharmaceutical composition for transdermal or transmucous administration of at least one active substance, comprising at least one fatty acid as percutaneous absorption promoter, at least one alcoholic vehicle, and also at least one stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition.
  • stable means a pharmaceutical composition whose qualitative and quantitative composition and whose physical, chemical and biological characteristics do not change significantly over time under given temperature and humidity conditions, i.e. for 3 years at 25° C./60% RH, for 1 year at 30° C./65% RH and/or for 6 months at 40° C./75% RH.
  • significant change means any qualitative and/or quantitative change, and also any change in the physical, chemical and biological characteristics that takes place outside the acceptance criteria defined for the analytical method used for each chemical, physical or biological test (numerical limit, interval or other relevant measurement).
  • the percutaneous absorption promoter(s) included in the pharmaceutical composition according to the invention is (are) preferably selected from the group consisting of saturated and unsaturated fatty acids.
  • fatty acids are preferably long-chain aliphatic fatty acids containing from 10 to 18 carbon atoms.
  • the fatty acids are selected, in a non-limiting manner, from the group consisting of capric acid (10:0), lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), stearic acid (18:0); oleic acid (18:1), palmitoleic acid (16:1), linoleic acid (18:2) and linolenic acid (18:3).
  • the fatty acid content in the pharmaceutical composition according to the present invention will advantageously be between 0.1% and 20%, preferably between 0.2% and 10% and even more preferably between 0.5% and 5%, these percentages being expressed by weight relative to 100 g of pharmaceutical composition.
  • composition according to the invention may contain other percutaneous absorption promoters in combination with the fatty acid(s).
  • the stabilizer is selected from the group consisting of buffers and/or fatty acid esters corresponding to the fatty acids present in the pharmaceutical composition as percutaneous absorption promoters.
  • the buffer(s) advantageously make it possible to maintain the pH of the said composition between 4 and 10, preferably between 5 and 9 and even more preferably between 6 and 8.
  • the buffer content of the pharmaceutical composition according to the invention is advantageously between 1% and 80%, preferably between 5% and 70% and even more preferably between 10% and 50%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the buffers are selected from the group consisting of:
  • the saturated or unsaturated fatty acid ester(s) used is (are) those that would result from the reaction between a fatty acid identical to that contained in the said composition, with an alcohol identical to that contained in the said composition.
  • the fatty acid esters are thus preferably selected from the group consisting of ethyl oleate, isopropyl oleate, isopropyl myristate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyl linoleate and ethyl linolenate.
  • the content of fatty acid ester added as stabilizer in the pharmaceutical composition according to the invention is advantageously between 0.1% and 10%, preferably between 0.2% and 5% and even more preferably between 0.5% and 2.5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the pharmaceutical composition according to the invention also contains a non-aqueous vehicle of alcohol type.
  • the alcoholic vehicle must be capable of dissolving all the components of the formulation and especially the fatty acid and the possible ester thereof.
  • the alcoholic vehicle may be selected from ethanol and/or isopropanol.
  • ethanol represents a preferred vehicle according to the invention since it contributes efficiently to the transcutaneous passage of the active principle by evaporating quickly on contact with the skin.
  • the alcohol content is advantageously between 10% and 90%, preferably between 20% and 80% and even more preferably between 40% and 70%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the pharmaceutical composition according to the invention may also comprise an aqueous vehicle.
  • the aqueous vehicle makes it possible to dissolve the hydrophilic molecules contained in the formulation and also promotes the diffusion of the lipophilic molecules of the formulation towards the horny layer. It forms a binary vehicle with the non-aqueous solvent.
  • the aqueous vehicle will preferably be water. Its content is between 1% and 80%, preferably between 10% and 70% and even more preferably between 20% and 60%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the pharmaceutical composition according to the invention may also contain a co-solvent such as polyols or polyglycols such as, for example, glycerol, propylene glycol or polyethylene glycol for a content of between 0.5% and 20%, and preferably between 1% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • a co-solvent such as polyols or polyglycols such as, for example, glycerol, propylene glycol or polyethylene glycol for a content of between 0.5% and 20%, and preferably between 1% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the co-solvent makes it possible to increase the solubility of the active substances.
  • the pharmaceutical composition according to the invention may be in the form of a gel, a solution, a cream, a lotion, a milk, an ointment, an aerosol or a patch.
  • It is preferably in the form of a gel or a solution.
  • the pharmaceutical composition according to the invention when in the form of a gel, it also comprises a gelling agent.
  • gelling agent has a content of between 0.2% and 30% of a gelling agent, preferably between 0.5% and 10% and even more preferably between 0.3% and 5%, these percentages being expressed on a weight basis per 100 g of pharmaceutical composition.
  • Carbomers or polyacrylic acids such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382 or 1382 NF, 5984, 2984 or 934 NF, Pemulen TR1 NF or TR2 NF, Ultrez, Synthalen CR, non-preneutralized acrylic polymers; cellulose derivatives such as ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), carboxymethyl cellulose (CMC), etc.; poloxamers or polyethylene polypropylene copolymers such as Lutrol F grade 68 or 127, poloxamines or other gelling agents such as chitosan, dextran, pectins and natural gums, alone or in combination, may be used as gelling agents in the pharmaceutical composition according to the invention.
  • Carbomers or polyacrylic acids such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382
  • gelling agents make it possible to increase the viscosity of the formulations according to the invention, but may also act as solubilizer.
  • Carbopol® 980 and/or hydroxypropylcellulose are particularly preferred in the context of the present invention.
  • the choice of the gelling agent will be made as a function of the pH of the composition defined according to the invention and of the desired viscosity.
  • the pharmaceutical composition according to the invention in the presence of certain types of gelling agents, and especially non-preneutralized acrylic polymers, it may contain a neutralizer.
  • the neutralizer/gelling agent ratio is then between 10/1 and 0.1/1, preferably between 7/1 and 0.5/1 and even more preferably between 4/1 and 1/1.
  • the neutralizer is chosen such that it forms, in the presence of the polymer, salts that are soluble in the vehicle.
  • the neutralizer is also chosen so as to be able to achieve optimum swelling of the polymer chains during the neutralization of the fillers and of the formation of polymer salts.
  • triethanolamine and/or tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) are preferably used as neutralizers in the presence of Carbopol® 980. They also make it possible to achieve an optimum viscosity in the pharmaceutical composition according to the invention.
  • neutralizers for instance sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine or aminomethylpropanol, may be used in the pharmaceutical composition according to the invention.
  • the neutralizer is chosen as a function of the type of gelling agent used, in a manner known to those skilled in the art.
  • the active substance(s) present in the pharmaceutical composition according to the invention may advantageously be selected from the group consisting of oestrogens, progestins, androgens, anti-oestrogens and anti-androgens, or mixtures thereof.
  • the active substance content is advantageously between 0.01% and 5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the anti-oestrogens may be selected from the group consisting of tamoxifen, 4-hydroxytamoxifen, tamoxifen citrate, toremifen, droloxifen and raloxifen.
  • the androgens may be selected from the group consisting of the natural androgen, testosterone, and its semi-natural or synthetic derivatives, for instance methyltestosterone; physiological precursors of testosterone such as dehydroepiandrosterone or DHEA, or alternatively prasterone and its derivatives, for instance DHEA sulphate, ⁇ -4-androstenedione and its derivatives; testosterone metabolites, for instance dihydrotestosterone (DHT) obtained after the enzymatic action of 5- ⁇ -reductases; or substances with an androgenic-type effect, such as tibolone.
  • DHT dihydrotestosterone
  • the anti-androgens may be selected from the group consisting of steroidal compounds such as cyproterone acetate, and medroxyprogesterone, or non-steroidal compounds such as flutamide, nilutamide or bicalutamide.
  • the active substance in the pharmaceutical composition according to the invention is preferably a progestin, an estrogen or a combination of the two.
  • the progestin(s) used in the pharmaceutical composition according to the invention may be selected from the group consisting of natural progestins, progesterone or its derivatives of ester type, and synthetic progestins of type 1, 2 or 3.
  • the first group comprises molecules similar to progesterone or the synthetic progestins 1 (SP1) (pregnanes), for example the progesterone isomer (retroprogesterone), medrogesterone, and norprogesterone derivatives (demegestone or promegestone).
  • the second group comprises 17 ⁇ -hydroxy-progesterone derivatives or synthetic progestins 2 (SP2) (pregnanes), for example cyproterone acetate and medroxyprogesterone acetate.
  • the third group comprises norsteroids or synthetic progestins 3 (SP3), (estranes or nor-androstanes). These are 19-nortestosterone derivatives, for example norethindrone.
  • This group also comprises molecules of gonane type, which are derived from these nor-androstanes or estranes and have a methyl group at C18 and an ethyl group at C13. Examples that may be mentioned include norgestimate, desogestrel (3-ketodesogestrel) or gestodene.
  • Tibolone which has both progestin and androgenic activity, may also advantageously be selected in the pharmaceutical composition according to the invention.
  • the oestrogen(s) used in the pharmaceutical composition according to the invention may advantageously be selected from the group consisting of natural oestrogens: 17 ⁇ -oestradiol, oestrone, equine conjugated oestrogens, estriol and phytoestrogens; semi-natural oestrogens: oestradiol valerate; or else synthetic oestrogens: ethinyl-estradiol; preferably 17 ⁇ -estradiol.
  • the progestin content will be between 0.01% and 5%, preferably between 0.02% and 3% and even more preferably between 0.03% and 1%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • the oestrogen content will be between 0.01% and 5%, preferably between 0.02% and 3% and even more preferably between 0.03% and 2%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • a first series of gels having the compositions given in Table I are subjected to stability tests.
  • the oleic acid and ethyl oleate contents were measured, respectively, by gas chromatography or by potentiometry (and by potentiometry) after storage at room temperature (25° C.) and 60% relative humidity, at times: 0, 1, 2, 3, 6, 10, 12 and 18 months (and 0, 1, 3, 4, 6, 12, 14 and 20 months for the placebo).
  • the specifications or standards given in the tables correspond to the set acceptance criterion which is plus or minus 5% relative to the initial theoretical value. Any value outside this acceptability range is considered non-compliant and corresponds to a “significant” variation. These values are given with grey shading in the tables.
  • Samples E858 to E865 contain a pH 10.7 carbonate/bicarbonate buffer. This buffer is loaded in place of the purified water during the preparation of the gel according to the invention. It was prepared in the following manner:
  • the specifications or standards given in the tables correspond to the set acceptance criterion, which is plus or minus 5% relative to the initial theoretical value. Any value outside this acceptability range is considered non-compliant and corresponds to a “significant” variation. These values are given with grey shading in the tables.
  • the gels were stored at 25° C. and 60% relative humidity, and at 40° C. and 75% relative humidity (accelerated ageing).
  • the oleic acid and ethyl oleate contents were measured as previously, at times: 0, 1, 2, 3 and 6 months.
  • the results are given in Table VI (25° C./60% RH) and VII (40° C./75% RH).
  • Part 1 Change in the oleic acid and ethyl oleate contents over time at 25° C./60% RH as a function of the composition of the gels (gels without stabilizer)
  • Part 2 Change in the oleic acid and ethyl oleate contents over time at 25° C./60% RH as a function of the composition of the gels (gels with stabilizer)
  • Part 1 Change in the oleic acid and ethyl oleate contents over time at 40° C./75% RH as a function of the composition of the gels (gels without stabilizer)
  • Part 2 Change in the oleic acid and ethyl oleate contents over time at 40° C./75% RH as a function of the composition of the gels (gels with stabilizer)

Abstract

The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition.

Description

  • The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising in particular a fatty acid as percutaneous absorption promoter, as well as a stabilizer capable of stabilizing the fatty acid in said pharmaceutical composition.
  • It is well known that certain active substances are not suitable for oral administration for various reasons associated, inter alia, either with a high level of metabolism in the liver: “1st passage effect”; or with a high level of gastrointestinal degradation.
  • Transdermal or transmucous formulations have thus been developed in order to circumvent these drawbacks.
  • Specifically, pharmaceutical compositions for transdermal or transmucous administration have several advantages over oral forms: elimination of the problem of metabolism of the active substance by the liver, no gastric degradation of the active substance, possible reservoir effect with continuous release of the active principle over time. However, they may pose problems as regards the passage of the active substances through the skin.
  • In fact, active substances do not all diffuse through the percutaneous barrier in a similar manner. This diffusion depends on the chemical and physicochemical characteristics of the molecule.
  • In order to facilitate this passage of the active substances through the skin, transdermal or transmucous formulations may include specific molecules known as “percutaneous absorption promoters”. This name is given to any molecule that promotes the reversible diffusion of an active principle through the skin or mucous membranes, and any solubilizing agent that promotes the partition of the active principle between the vehicle and the horny layer of the epidermis or of the mucous membranes. One of the classes of absorption promoters commonly used in transdermal or transmucous formulations is the class of fatty acids.
  • However, the Applicant Company has shown that aqueous-alcoholic compositions containing these fatty acids are not chemically stable. Specifically, on account of its “acid” function and in the presence of alcohol, the fatty acid undergoes an esterification reaction according to the laws of organic chemistry. Thus, for example, oleic acid is converted into ethyl oleate in the presence of ethanol.
  • However, since medicinal products are often stored for a certain amount of time before being sold, it is essential for their composition to be invariable so as to ensure patient health safety. Any medicinal product must therefore demonstrate high stability, i.e. its composition must not vary over time. Stability of the pharmaceutical composition is a guarantee of consistency in terms of bioavailability of the active agent, efficacy of the pharmaceutical composition, and acceptability and harmlessness of the medicinal product for the patient.
  • Thus, in a gel or an aqueous-alcoholic solution, if there is appreciable degradation of the fatty acid, acting as percutaneous absorption promoter of the active substance, this may considerably change the bioavailability of the active substance and thus its efficacy.
  • The Applicant Company has performed extensive studies and research in order to provide a solution to this problem of stability of fatty acids in alcoholic medium, in order to obtain satisfactory stability.
  • The Applicant Company has thus found that it is possible to stabilize the fatty acid in the pharmaceutical composition by adding a buffer and/or by adding small amounts of an ester of the corresponding acid, at the time of preparation of said pharmaceutical composition.
  • The invention thus relates to a pharmaceutical composition for transdermal or transmucous administration of at least one active substance, comprising at least one fatty acid as percutaneous absorption promoter, at least one alcoholic vehicle, and also at least one stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition.
  • In the context of the present invention, the term “stable” means a pharmaceutical composition whose qualitative and quantitative composition and whose physical, chemical and biological characteristics do not change significantly over time under given temperature and humidity conditions, i.e. for 3 years at 25° C./60% RH, for 1 year at 30° C./65% RH and/or for 6 months at 40° C./75% RH.
  • The term “significant change” means any qualitative and/or quantitative change, and also any change in the physical, chemical and biological characteristics that takes place outside the acceptance criteria defined for the analytical method used for each chemical, physical or biological test (numerical limit, interval or other relevant measurement).
  • The percutaneous absorption promoter(s) included in the pharmaceutical composition according to the invention is (are) preferably selected from the group consisting of saturated and unsaturated fatty acids.
  • They are preferably long-chain aliphatic fatty acids containing from 10 to 18 carbon atoms. The fatty acids are selected, in a non-limiting manner, from the group consisting of capric acid (10:0), lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), stearic acid (18:0); oleic acid (18:1), palmitoleic acid (16:1), linoleic acid (18:2) and linolenic acid (18:3).
  • The fatty acid content in the pharmaceutical composition according to the present invention will advantageously be between 0.1% and 20%, preferably between 0.2% and 10% and even more preferably between 0.5% and 5%, these percentages being expressed by weight relative to 100 g of pharmaceutical composition.
  • However, it is explicitly indicated here that the pharmaceutical composition according to the invention may contain other percutaneous absorption promoters in combination with the fatty acid(s).
  • The stabilizer is selected from the group consisting of buffers and/or fatty acid esters corresponding to the fatty acids present in the pharmaceutical composition as percutaneous absorption promoters.
  • When they are present in the pharmaceutical composition according to the invention, the buffer(s) advantageously make it possible to maintain the pH of the said composition between 4 and 10, preferably between 5 and 9 and even more preferably between 6 and 8.
  • The buffer content of the pharmaceutical composition according to the invention is advantageously between 1% and 80%, preferably between 5% and 70% and even more preferably between 10% and 50%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • According to one preferred embodiment of the pharmaceutical composition according to the invention, the buffers are selected from the group consisting of:
      • basifying or basic buffers such as a phosphate buffer (for example dibasic or monobasic sodium phosphate), a citrate buffer (for example sodium citrate or potassium citrate), sodium carbonate, sodium bicarbonate, a mixture of sodium carbonate and sodium bicarbonate being preferable, or
      • neutral buffers such as a Tris buffer, preferably a phosphate buffer.
  • According to another embodiment of the pharmaceutical composition according to the invention, the saturated or unsaturated fatty acid ester(s) used is (are) those that would result from the reaction between a fatty acid identical to that contained in the said composition, with an alcohol identical to that contained in the said composition. The fatty acid esters are thus preferably selected from the group consisting of ethyl oleate, isopropyl oleate, isopropyl myristate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyl linoleate and ethyl linolenate.
  • The content of fatty acid ester added as stabilizer in the pharmaceutical composition according to the invention is advantageously between 0.1% and 10%, preferably between 0.2% and 5% and even more preferably between 0.5% and 2.5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • The pharmaceutical composition according to the invention also contains a non-aqueous vehicle of alcohol type. The alcoholic vehicle must be capable of dissolving all the components of the formulation and especially the fatty acid and the possible ester thereof. Preferably, the alcoholic vehicle may be selected from ethanol and/or isopropanol. However, ethanol represents a preferred vehicle according to the invention since it contributes efficiently to the transcutaneous passage of the active principle by evaporating quickly on contact with the skin.
  • The alcohol content is advantageously between 10% and 90%, preferably between 20% and 80% and even more preferably between 40% and 70%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • The pharmaceutical composition according to the invention may also comprise an aqueous vehicle. The aqueous vehicle makes it possible to dissolve the hydrophilic molecules contained in the formulation and also promotes the diffusion of the lipophilic molecules of the formulation towards the horny layer. It forms a binary vehicle with the non-aqueous solvent.
  • The aqueous vehicle will preferably be water. Its content is between 1% and 80%, preferably between 10% and 70% and even more preferably between 20% and 60%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • The pharmaceutical composition according to the invention may also contain a co-solvent such as polyols or polyglycols such as, for example, glycerol, propylene glycol or polyethylene glycol for a content of between 0.5% and 20%, and preferably between 1% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition. The co-solvent makes it possible to increase the solubility of the active substances.
  • The pharmaceutical composition according to the invention may be in the form of a gel, a solution, a cream, a lotion, a milk, an ointment, an aerosol or a patch.
  • It is preferably in the form of a gel or a solution.
  • When the pharmaceutical composition according to the invention is in the form of a gel, it also comprises a gelling agent.
  • Advantageously, and depending on the type of gelling agent used, it has a content of between 0.2% and 30% of a gelling agent, preferably between 0.5% and 10% and even more preferably between 0.3% and 5%, these percentages being expressed on a weight basis per 100 g of pharmaceutical composition.
  • Carbomers or polyacrylic acids such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382 or 1382 NF, 5984, 2984 or 934 NF, Pemulen TR1 NF or TR2 NF, Ultrez, Synthalen CR, non-preneutralized acrylic polymers; cellulose derivatives such as ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), carboxymethyl cellulose (CMC), etc.; poloxamers or polyethylene polypropylene copolymers such as Lutrol F grade 68 or 127, poloxamines or other gelling agents such as chitosan, dextran, pectins and natural gums, alone or in combination, may be used as gelling agents in the pharmaceutical composition according to the invention.
  • These gelling agents make it possible to increase the viscosity of the formulations according to the invention, but may also act as solubilizer.
  • Carbopol® 980 and/or hydroxypropylcellulose are particularly preferred in the context of the present invention.
  • The choice of the gelling agent will be made as a function of the pH of the composition defined according to the invention and of the desired viscosity.
  • According to another advantageous embodiment of the pharmaceutical composition according to the invention, in the presence of certain types of gelling agents, and especially non-preneutralized acrylic polymers, it may contain a neutralizer. The neutralizer/gelling agent ratio is then between 10/1 and 0.1/1, preferably between 7/1 and 0.5/1 and even more preferably between 4/1 and 1/1.
  • The neutralizer is chosen such that it forms, in the presence of the polymer, salts that are soluble in the vehicle.
  • The neutralizer is also chosen so as to be able to achieve optimum swelling of the polymer chains during the neutralization of the fillers and of the formation of polymer salts.
  • According to the invention, triethanolamine and/or tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) are preferably used as neutralizers in the presence of Carbopol® 980. They also make it possible to achieve an optimum viscosity in the pharmaceutical composition according to the invention.
  • Other neutralizers, for instance sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine or aminomethylpropanol, may be used in the pharmaceutical composition according to the invention. The neutralizer is chosen as a function of the type of gelling agent used, in a manner known to those skilled in the art.
  • The active substance(s) present in the pharmaceutical composition according to the invention may advantageously be selected from the group consisting of oestrogens, progestins, androgens, anti-oestrogens and anti-androgens, or mixtures thereof.
  • The active substance content is advantageously between 0.01% and 5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • The anti-oestrogens may be selected from the group consisting of tamoxifen, 4-hydroxytamoxifen, tamoxifen citrate, toremifen, droloxifen and raloxifen.
  • The androgens may be selected from the group consisting of the natural androgen, testosterone, and its semi-natural or synthetic derivatives, for instance methyltestosterone; physiological precursors of testosterone such as dehydroepiandrosterone or DHEA, or alternatively prasterone and its derivatives, for instance DHEA sulphate, Δ-4-androstenedione and its derivatives; testosterone metabolites, for instance dihydrotestosterone (DHT) obtained after the enzymatic action of 5-α-reductases; or substances with an androgenic-type effect, such as tibolone.
  • The anti-androgens may be selected from the group consisting of steroidal compounds such as cyproterone acetate, and medroxyprogesterone, or non-steroidal compounds such as flutamide, nilutamide or bicalutamide. The active substance in the pharmaceutical composition according to the invention is preferably a progestin, an estrogen or a combination of the two.
  • Advantageously, the progestin(s) used in the pharmaceutical composition according to the invention may be selected from the group consisting of natural progestins, progesterone or its derivatives of ester type, and synthetic progestins of type 1, 2 or 3. The first group comprises molecules similar to progesterone or the synthetic progestins 1 (SP1) (pregnanes), for example the progesterone isomer (retroprogesterone), medrogesterone, and norprogesterone derivatives (demegestone or promegestone). The second group comprises 17α-hydroxy-progesterone derivatives or synthetic progestins 2 (SP2) (pregnanes), for example cyproterone acetate and medroxyprogesterone acetate. The third group comprises norsteroids or synthetic progestins 3 (SP3), (estranes or nor-androstanes). These are 19-nortestosterone derivatives, for example norethindrone. This group also comprises molecules of gonane type, which are derived from these nor-androstanes or estranes and have a methyl group at C18 and an ethyl group at C13. Examples that may be mentioned include norgestimate, desogestrel (3-ketodesogestrel) or gestodene.
  • Tibolone, which has both progestin and androgenic activity, may also advantageously be selected in the pharmaceutical composition according to the invention.
  • The oestrogen(s) used in the pharmaceutical composition according to the invention may advantageously be selected from the group consisting of natural oestrogens: 17β-oestradiol, oestrone, equine conjugated oestrogens, estriol and phytoestrogens; semi-natural oestrogens: oestradiol valerate; or else synthetic oestrogens: ethinyl-estradiol; preferably 17β-estradiol.
  • According to one advantageous embodiment of the pharmaceutical composition according to the invention, the progestin content will be between 0.01% and 5%, preferably between 0.02% and 3% and even more preferably between 0.03% and 1%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • According to another particular embodiment of the pharmaceutical composition according to the invention, the oestrogen content will be between 0.01% and 5%, preferably between 0.02% and 3% and even more preferably between 0.03% and 2%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
  • The invention will be understood more clearly with the aid of the non-limiting examples described below.
    • EXAMPLE 1 Instability of Gels Comprising Oleic Acid
  • A first series of gels having the compositions given in Table I are subjected to stability tests.
      • The manufacture of a gel according to the invention is performed as follows:
      • For 40 kg of a gel manufactured according to formulation E760 containing two active principles, Estradiol (Diosynth) and Progesterone (Xianming):
        • 26 000 g of 95° ethanol are introduced into a Koruma mixer tank under a vacuum of 800 mbar.
        • Next, 2000 g de propylene glycol and 1200 g of oleic acid are successively loaded via the top of the tank, without stirring. The mixture is stirred for at least 5 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
        • 24.8 g of Estradiol are added. The mixture is then mixed for 15 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
        • 800 g of progesterone are added. The mixture is then mixed for 15 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
        • 400 g of Klucel®HF are introduced under a vacuum of 800 mbar, with the turbomixer at 1500 rpm.
        • The mixture is stirred for at least 10 minutes, with the turbomixer at 1500 rpm and the doctor blade at 40 rpm.
        • Next, purified water is added in an amount sufficient to obtain a total mass of 40 000 g, under a vacuum of 800 mbar, with the doctor blade at 40 rpm.
        • The mixture is stirred for at least 10 minutes, with the turbomixer at 1500 rpm and the doctor blade at 40 rpm.
        • The turbomixer is switched off.
        • A vacuum of 100 mbar is applied for about 2 minutes.
        • The mixture is stirred gently for at least 10 minutes, with the doctor blade at 10 rpm.
  • The other formulations are prepared in the same manner, the amounts of the various components being modified according to Table I.
  • The oleic acid and ethyl oleate contents were measured, respectively, by gas chromatography or by potentiometry (and by potentiometry) after storage at room temperature (25° C.) and 60% relative humidity, at times: 0, 1, 2, 3, 6, 10, 12 and 18 months (and 0, 1, 3, 4, 6, 12, 14 and 20 months for the placebo).
  • The results are given in Tables II and III.
  • The specifications or standards given in the tables correspond to the set acceptance criterion which is plus or minus 5% relative to the initial theoretical value. Any value outside this acceptability range is considered non-compliant and corresponds to a “significant” variation. These values are given with grey shading in the tables.
  • TABLE I
    Composition of the aqueous-alcoholic gels tested
    Samples
    E751
    placebo E760 E761 E762 E763
    % Progesterone 0 2 2 3 3
    % Estradiol 0 0.06 0.06 0.06 0.06
    % propylene glycol 5 5 5 5 5
    % oleic acid 2 3 3 2 2
    % Klucel ®* 1.5 1 1.5 1 1.5
    95% EtOH v/v 65 65 65 65 65
    purified water qs 100 g qs qs qs 100 g qs 100 g
    100 g 100 g
    *Hydroxypropyl cellulose manufactured by the company Aqualon.
  • An accelerated ageing test was also performed on the same gels which were stored at a temperature of 40° C. with a relative humidity of 75%, at times 0, 1, 2, 3, 4, 5, 6, 10, 11, 12 and 18 months. The oleic acid and ethyl oleate contents were then measured as previously, at the same times. The results are given in Table IV.
  • Significant esterification of the oleic acid is observed in all the gels during ageing. The content of ethyl oleate formed and the rate of esterification are proportionately higher the larger the starting percentage of oleic acid and the higher the temperature and humidity conditions (difference between 25° C./60% RH and 40° C./75% RH).
  • This esterification of oleic acid raises two major concerns relating to the integrity of the pharmaceutical specialty product:
      • ethyl oleate is sparingly soluble in alcohol, which may lead to an undesired emulsion in the gel;
      • since oleic acid has been selected for its role as a percutaneous absorption promoter, a reduction in its content will result in a harmful effect on the percutaneous passage of the active substances.
  • TABLE II
    Change in the oleic acid and ethyl oleate contents over time at
    25° C./60% RH as a function of the composition of the gels
    Figure US20100048526A1-20100225-C00001
  • TABLE III
    Change in the oleic acid and ethyl oleate con:ents over time at
    25° C./60% RH on the placebo gel
    Figure US20100048526A1-20100225-C00002
    *NP: not performed
  • TABLE IV
    Change in the oleic acid and ethyl oleate contents over time at 40° C./75% RH as a
    function of the composition of the gels
    Figure US20100048526A1-20100225-C00003
    THE GREY SHADING SHOULD BE REMOVED FROM BATCH E 762 at 6.6% EO.
    • EXAMPLE 2 Instability of Gels Comprising Oleic Acid and Stabilization Thereof According to the Invention
  • A second series of gels having the compositions given in Table V was subjected to stability tests.
      • The manufacture of a gel according to the invention is performed as follows:
      • Specifically, for 30 kg of a gel manufactured according to the formulation E844 containing two active principles Estradiol (Diosynth) and Progesterone (Xianming):
      • 19 500 g of 95° ethanol are placed in a Koruma mixer tank under a vacuum of 800 mbar.
      • Next, 1500 g of propylene glycol and 1500 g of oleic acid are successively loaded via the top of the tank, without stirring. The mixture is stirred for at least 5 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
      • 18.6 g of Estradiol are added. Next, the mixture is stirred for 15 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
      • 600 g of Progesterone are added. The mixture is then stirred for 15 minutes, with the turbomixer at 2000 rpm and the doctor blade at 40 rpm.
      • 300 g of Klucel®HF are introduced under a vacuum of 800 mbar, with the turbomixer at 1500 rpm.
      • The mixture is stirred for at least 10 minutes, with the turbomixer at 1500 rpm and the doctor blade at 40 rpm.
      • Next, purified water is added in an amount sufficient for 30 000 g, under a vacuum of 800 mbar, with the doctor blade at 40 rpm.
      • The mixture is stirred for at least 10 minutes, with the turbomixer at 1500 rpm and the doctor blade at 40 rpm.
      • The turbomixer is switched off.
      • A vacuum of 100 mbar is applied for about 2 minutes.
      • The mixture is stirred gently for at least 10 minutes, with the doctor blade at 10 rpm.
  • The other formulations E 845 to E 854 were prepared in the same manner, the amounts of compounds introduced being varied according to Table V.
  • Samples E858 to E865 contain a pH 10.7 carbonate/bicarbonate buffer. This buffer is loaded in place of the purified water during the preparation of the gel according to the invention. It was prepared in the following manner:
      • 0.2M solution of anhydrous Na2CO3 in purified water, ie: 21.2 g/l (Solution A), was prepared.
      • A 0.2M solution of NaHCO3 in purified water, ie: 16.8 g/l (solution B), was prepared.
      • 21.3 ml of solution A were then added to 3.8 ml of solution B and water was added to obtain 100 ml. The resulting solution corresponds to the buffer used in tests E858 to E 865. The pH of this buffer solution is 10.7.
  • The specifications or standards given in the tables correspond to the set acceptance criterion, which is plus or minus 5% relative to the initial theoretical value. Any value outside this acceptability range is considered non-compliant and corresponds to a “significant” variation. These values are given with grey shading in the tables.
  • The gels were stored at 25° C. and 60% relative humidity, and at 40° C. and 75% relative humidity (accelerated ageing). The oleic acid and ethyl oleate contents were measured as previously, at times: 0, 1, 2, 3 and 6 months. The results are given in Table VI (25° C./60% RH) and VII (40° C./75% RH).
  • These analyses demonstrate that the use of the carbonate/bicarbonate buffer at pH 10.7 significantly reduces the esterification of oleic acid to ethyl oleate.
  • TABLE V
    Composition of the aqueous-alcoholic gels E844 to 865
    Polypropylene Oleic ETOH 95% qs
    Progesterone % Estradiol % Glycol % acid % KLUCELa % V/V % Isopropanol % 100 g
    E 844 2 0.06 5 5 1 65 0 water
    E*845 2 0.06 5 5 1 65 0 water
    E 846 3 0.06 5 5 1 65 0 water
    E*847 3 0.06 5 5 1 65 0 water
    E 848 3 0.06 5 5 1.5 65 0 water
    E*849 3 0.06 5 5 1.5 65 0 water
    E 850 3 0.06 5 2 1 65 0 water
    E*851 3 0.06 5 2 1 65 0 water
    E 852 2 0.06 5 5 1.5 65 0 water
    E*853 2 0.06 5 5 1.5 65 0 water
    E 854 3 0.06 5 2 1.5 65 0 water
    E*855 3 0.06 5 2 1.5 65 0 water
    E 858 2 0.06 5 5 1 65 0 buffer
    E*859 2 0.06 5 5 1 65 0 buffer
    E 861 3 0.06 5 2 1 65 0 buffer
    E*862 3 0.06 5 2 1 65 0 buffer
    E 863 3 0.06 5 5 1 65 0 buffer
    E*864 3 0.06 5 5 1 65 0 buffer
    E 865 5 0.06 5 3 1 30 35 buffer
    aHydroxypropyl cellulose manufactured by the company Aqualon.
    *Supplier = SCHERING - for the other batches, supplier = DIOSYNTH
  • TABLE VI
    (part 1): Change in the oleic acid and ethyl oleate contents over time
    at 25° C./60% RH as a function of the composition of the gels (gels without stabilizer)
    Figure US20100048526A1-20100225-C00004
    (part 2): Change in the oleic acid and ethyl oleate contents over time at
    25° C./60% RH as a function of the composition of the gels (gels with stabilizer)
    Figure US20100048526A1-20100225-C00005
  • TABLE VII
    (part 1): Change in the oleic acid and ethyl oleate contents over time at
    40° C./75% RH as a function of the composition of the gels (gels without stabilizer)
    Figure US20100048526A1-20100225-C00006
    (part 2): Change in the oleic acid and ethyl oleate contents over time at
    40° C./75% RH as a function of the composition of the gels (gels with stabilizer)
    Figure US20100048526A1-20100225-C00007

Claims (37)

1.-21. (canceled)
22. A pharmaceutical composition for transdermal or transmucous administration of at least one active substance, comprising
an active substance,
a fatty acid percutaneous absorption promoter,
an alcoholic vehicle comprising an alcohol, and
a fatty acid ester capable of stabilizing the fatty acid in said pharmaceutical composition.
23. A pharmaceutical composition according to claim 22, wherein the fatty acid is selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, palmitoleic acid, linoleic acid and linolenic acid.
24. A pharmaceutical composition according to claim 22, having a fatty acid content between 0.1% and 20%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
25. A pharmaceutical composition according to claim 22, having a fatty acid content of between 0.2% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
26. A pharmaceutical composition according to claim 22, having a fatty acid content of between 0.5% and 5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
27. A pharmaceutical composition according to claim 22, wherein the fatty acid ester is selected from the group consisting of ethyl oleate, isopropyl oleate, isopropyl myristate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyl linoleate and ethyl linolenate.
28. A pharmaceutical composition according to claim 22, having a fatty acid ester content of between 0.1% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
29. A pharmaceutical composition according to claim 22, having a fatty acid ester content of between 0.2% and 5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
30. A pharmaceutical composition according to claim 22, having a fatty acid ester content of between 0.5% and 2.5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
31. A pharmaceutical composition according to claim 22, wherein the alcoholic vehicle comprises ethanol.
32. A pharmaceutical composition according to claim 22, wherein the alcoholic vehicle comprises isopropanal.
33. A pharmaceutical composition according to claim 22, having an alcoholic vehicle content of between 10% and 90%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
34. A pharmaceutical composition according to claim 22, having an alcoholic vehicle content of between 20% and 80%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
35. A pharmaceutical composition according to claim 22, having an alcoholic vehicle content of between 40% and 70%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
36. A pharmaceutical composition according to claim 22, further comprising a co-solvent selected from the group consisting of glycerol, propylene glycol, polyethylene glycol, and mixtures thereof.
37. A pharmaceutical composition according to claim 36, having a co-solvent content of between 0.5% and 20%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
38. A pharmaceutical composition according to claim 36, having a co-solvent content of between 1% and 10%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
39. A pharmaceutical composition according to claim 22, wherein said composition is in the form of a gel, a solution, a cream, a lotion, a milk, an ointment, an aerosol or a patch.
40. A pharmaceutical composition according to claim 22, wherein said composition is in the form of a gel or a solution.
41. A pharmaceutical composition according to claim 22, being in the form of a gel, and further comprising between 0.2% and 30% of a gelling agent, these percentages being expressed on a weight basis relative to 100 g of formulation.
42. A pharmaceutical composition according to claim 22, being in the form of a gel, and further comprising between 0.5% and 10% of a gelling agent, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
43. A pharmaceutical composition according to claim 22, being in the form of a gel, and-further comprising between 0.3% and 5% of a gelling agent, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
44. A pharmaceutical composition according to claim 41, wherein the gelling agent is selected from the group consisting of carbomers, non-preneutralized acrylic polymers, cellulose derivatives, poloxamers, poloxamines, chitosan, dextran pectins, natural gums, and mixtures thereof.
45. A pharmaceutical composition according to claim 41, wherein the gelling agent is selected from the group consisting of carbomers, cellulose derivatives, and mixtures thereof.
46. A pharmaceutical composition according to claim 41, wherein the gelling agent is selected from the group consisting of Carbopol® 980, hydroxypropylcellulose and mixtures thereof.
47. A pharmaceutical composition according to claim 41, further comprising a neutralizer.
48. A pharmaceutical composition according to claim 47, wherein the neutralizer is selected from the group consisting of triethanolamine, sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethylpropanol and tromethamine, and mixtures thereof.
49. A pharmaceutical composition according to claim 47, wherein the neutralizer is selected from the group consisting of triethanolamine, tromethamine, and mixtures thereof.
50. A pharmaceutical composition according to claim 47, wherein the neutralizer/gelling agent ratio is between 10/1 and 0.1/1.
51. A pharmaceutical composition according to claim 47, wherein the neutralizer/gelling agent ratio is between 7/1 and 0.5/1.
52. A pharmaceutical composition according to claim 47, wherein the neutralizer/gelling agent ratio is between 4/1 and 1/1.
53. A pharmaceutical composition according to claim 22, wherein the active substance is selected from the group consisting of oestrogens, progestins, androgens, anti-oestrogens and anti-androgens, and mixtures thereof.
54. A pharmaceutical composition according to claim 53, having an active substance content of between 0.01% and 5%, these percentages being expressed on a weight basis relative to 100 g of pharmaceutical composition.
55. A pharmaceutical composition according to claim 22, having a pH of between 4 and 10.
56. A pharmaceutical composition according to claim 22, having a pH of between 5 and 9.
57. A pharmaceutical composition according to claim 22, having a pH of between 6 and 8.
US12/609,473 2003-02-20 2009-10-30 Pharmaceutical composition for transdermal or transmucous administration Abandoned US20100048526A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/609,473 US20100048526A1 (en) 2003-02-20 2009-10-30 Pharmaceutical composition for transdermal or transmucous administration
US13/353,667 US20120122829A1 (en) 2003-02-20 2012-01-19 Pharmaceutical composition for transdermal or transmucous administration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0302083A FR2851470B1 (en) 2003-02-20 2003-02-20 PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
FRFR0302083 2003-02-20
US10/436,380 US7611727B2 (en) 2003-02-20 2003-05-12 Pharmaceutical composition for transdermal or transmucous administration
US12/609,473 US20100048526A1 (en) 2003-02-20 2009-10-30 Pharmaceutical composition for transdermal or transmucous administration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/436,380 Continuation US7611727B2 (en) 2003-02-20 2003-05-12 Pharmaceutical composition for transdermal or transmucous administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/353,667 Continuation US20120122829A1 (en) 2003-02-20 2012-01-19 Pharmaceutical composition for transdermal or transmucous administration

Publications (1)

Publication Number Publication Date
US20100048526A1 true US20100048526A1 (en) 2010-02-25

Family

ID=32799454

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/436,380 Active 2024-11-28 US7611727B2 (en) 2003-02-20 2003-05-12 Pharmaceutical composition for transdermal or transmucous administration
US12/609,473 Abandoned US20100048526A1 (en) 2003-02-20 2009-10-30 Pharmaceutical composition for transdermal or transmucous administration
US13/353,667 Abandoned US20120122829A1 (en) 2003-02-20 2012-01-19 Pharmaceutical composition for transdermal or transmucous administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/436,380 Active 2024-11-28 US7611727B2 (en) 2003-02-20 2003-05-12 Pharmaceutical composition for transdermal or transmucous administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/353,667 Abandoned US20120122829A1 (en) 2003-02-20 2012-01-19 Pharmaceutical composition for transdermal or transmucous administration

Country Status (6)

Country Link
US (3) US7611727B2 (en)
EP (1) EP1990061A3 (en)
JP (1) JP4925103B2 (en)
DE (1) DE602004017700D1 (en)
FR (1) FR2851470B1 (en)
HK (1) HK1084590A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118242A1 (en) * 2000-08-30 2005-06-02 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20050152956A1 (en) * 2000-08-30 2005-07-14 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US20110098258A1 (en) * 2009-10-27 2011-04-28 Besins Healthcare Luxembourg Transdermal Pharmaceutical Compositions Comprising Active Agents
US20110118226A1 (en) * 2008-07-24 2011-05-19 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US20110172196A1 (en) * 2000-08-30 2011-07-14 Dudley Robert E Pharmaceutical composition and method for treating hypogonadism
US8466136B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
UA80964C2 (en) * 2002-03-15 2007-11-26 Unimed Pharmaceuticals Inc Method for treating depression and kit therefor
KR20050045946A (en) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 Transdermal delivery rate control using amorphous pharmaceutical compositions
FR2851470B1 (en) * 2003-02-20 2007-11-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
CN102091079B (en) * 2005-06-03 2014-03-12 艾克若克斯Dds有限公司 Method and composition for transdermal drug delivery
MX2007015255A (en) * 2005-06-03 2008-02-22 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery.
US8920821B2 (en) * 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US10278917B2 (en) 2006-04-14 2019-05-07 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US9050293B2 (en) * 2008-07-16 2015-06-09 Juventio, Llc Small molecule solubilization system
SI2373305T1 (en) * 2008-12-11 2017-09-29 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising a serm
WO2013052849A2 (en) * 2011-10-07 2013-04-11 Florida State University Research Foundation Prophylactic and post-acute use of progesterone to better outcomes associated with concussion
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5778984A (en) * 1996-03-22 1998-07-14 Ebisu Science Laboratory Inc. Fluid fire extinguishing agent shell for throwing
US5891462A (en) * 1996-06-06 1999-04-06 Permatec N.V. Composition for transdermal administration of an estrogen
US20030092754A1 (en) * 1999-07-16 2003-05-15 Nishizumi Nishimuta External preparation for skin diseases containing nitroimidazole
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20030181430A1 (en) * 2000-09-15 2003-09-25 Georges Gray Novel topical oestroprogestational compositions with a systemic effect
US20040001881A1 (en) * 2000-03-30 2004-01-01 Thorsten Selzer Transdermal therapeutic system for delivering lerisetron
US20040110732A1 (en) * 2002-12-10 2004-06-10 Besins International Belgique Pharmaceutical composition for transdermal or transmucosal administration comprising at least one progestin and/or at least one oestrogen, process for preparing it and uses thereof
US7611727B2 (en) * 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518879A1 (en) 1981-12-30 1983-07-01 Besins Jean Topical oestradiol compsns. - for treatment of disorders associated with menopause
JPH0798935B2 (en) * 1987-11-25 1995-10-25 有限会社野々川商事 Quality deterioration inhibitor
DE68920109T2 (en) 1988-10-11 1995-05-11 Shire Holdings Ltd Drug preparation for percutaneous absorption.
EP0370220B1 (en) 1988-10-27 1996-01-10 Schering Aktiengesellschaft Gestode composition for transdermal application
CA2091883A1 (en) 1990-10-29 1992-04-30 Robert M. Gale Transdermal contraceptive formulations, methods and devices
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
DE4227989A1 (en) 1992-08-21 1994-06-09 Schering Ag Agent for transdermal application containing 3-keto-desogestrel
JPH0782147A (en) * 1993-09-14 1995-03-28 Dot:Kk Indomethacin farnesyl-containing external preparation
BR9408457A (en) 1993-12-27 1997-08-05 Akzo Nobel Nv Percutaneous pharmaceutical preparation
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
RU2122396C1 (en) 1996-07-12 1998-11-27 Валентина Александровна Андрюшина Bioactive addition to cosmetics
JPH1087488A (en) * 1996-09-13 1998-04-07 Sekisui Chem Co Ltd Preparation for external use for treating dermatosis
EP0971662A1 (en) 1996-10-30 2000-01-19 TheraTech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers
KR100215027B1 (en) 1997-01-27 1999-08-16 성재갑 Composition for transdermal administration of steroid drugs and formulation containing same
JP2000026285A (en) * 1998-07-10 2000-01-25 Nitto Denko Corp Plaster
SE9703458D0 (en) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
DK1510213T3 (en) 1997-11-10 2009-03-23 Strakan Int Ltd Penetration-enhancing and irritation-reducing systems including testosterone
AU1689999A (en) 1997-12-25 1999-07-19 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
JP2001163783A (en) * 1999-09-28 2001-06-19 Shoei:Kk Agent for external use for treating dermatosis
AR030312A1 (en) 2000-08-03 2003-08-20 Antares Pharma Ipl Ag NEW COMPOSITION FOR THE TRANSDERMAL AND / OR TRANSMUCOSICAL ADMINISTRATION OF ACTIVE COMPOUNDS, WHICH ENSURES PROPER THERAPEUTIC LEVELS
KR100416646B1 (en) * 2000-08-14 2004-02-05 구주제약주식회사 Hydrogel Preparation of Lidocaine Microemulsion for the Treatment of Premature Ejaculation
JP2002212105A (en) 2001-01-22 2002-07-31 Lion Corp Aqueous skin care composition

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5778984A (en) * 1996-03-22 1998-07-14 Ebisu Science Laboratory Inc. Fluid fire extinguishing agent shell for throwing
US5891462A (en) * 1996-06-06 1999-04-06 Permatec N.V. Composition for transdermal administration of an estrogen
US20030092754A1 (en) * 1999-07-16 2003-05-15 Nishizumi Nishimuta External preparation for skin diseases containing nitroimidazole
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US20040001881A1 (en) * 2000-03-30 2004-01-01 Thorsten Selzer Transdermal therapeutic system for delivering lerisetron
US20030181430A1 (en) * 2000-09-15 2003-09-25 Georges Gray Novel topical oestroprogestational compositions with a systemic effect
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040110732A1 (en) * 2002-12-10 2004-06-10 Besins International Belgique Pharmaceutical composition for transdermal or transmucosal administration comprising at least one progestin and/or at least one oestrogen, process for preparing it and uses thereof
US7611727B2 (en) * 2003-02-20 2009-11-03 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118242A1 (en) * 2000-08-30 2005-06-02 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20050152956A1 (en) * 2000-08-30 2005-07-14 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US20110172196A1 (en) * 2000-08-30 2011-07-14 Dudley Robert E Pharmaceutical composition and method for treating hypogonadism
US20110201586A1 (en) * 2000-08-30 2011-08-18 Dudley Robert E Pharmaceutical composition and method for treating hypogonadism
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US8741881B2 (en) 2005-10-12 2014-06-03 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466138B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466137B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8486925B2 (en) 2005-10-12 2013-07-16 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8729057B2 (en) 2005-10-12 2014-05-20 Unimed Pharmaeuticals, LLC Testosterone gel and method of use
US8466136B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8754070B2 (en) 2005-10-12 2014-06-17 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8759329B2 (en) 2005-10-12 2014-06-24 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US20110118226A1 (en) * 2008-07-24 2011-05-19 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US20110098258A1 (en) * 2009-10-27 2011-04-28 Besins Healthcare Luxembourg Transdermal Pharmaceutical Compositions Comprising Active Agents
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US11040043B2 (en) 2009-10-27 2021-06-22 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents

Also Published As

Publication number Publication date
HK1084590A1 (en) 2006-08-04
FR2851470A1 (en) 2004-08-27
EP1990061A3 (en) 2011-09-07
FR2851470B1 (en) 2007-11-16
EP1990061A2 (en) 2008-11-12
US20120122829A1 (en) 2012-05-17
DE602004017700D1 (en) 2008-12-24
JP4925103B2 (en) 2012-04-25
US20040175416A1 (en) 2004-09-09
US7611727B2 (en) 2009-11-03
JP2006518359A (en) 2006-08-10

Similar Documents

Publication Publication Date Title
US7611727B2 (en) Pharmaceutical composition for transdermal or transmucous administration
US11040043B2 (en) Transdermal pharmaceutical compositions comprising active agents
US7030104B2 (en) Topical oestroprogestational compositions with a systemic effect
US20190070197A1 (en) Transdermal cream
US10016442B2 (en) Estrogen compositions for vaginal administration
US20070004693A1 (en) Estrogen compositions for vaginal administration
US20070287688A1 (en) Pharmaceutical Compositions for Topical Application
US20110027369A1 (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JP2010241824A (en) Pharmaceutical composition in the form of hydrogel for transdermal administration of active substance
JPH0676327B2 (en) Steroid ointment formulation
EP1594545B1 (en) Pharmaceutical composition for transdermal or transmucosal administration

Legal Events

Date Code Title Description
AS Assignment

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, LUXEMBOURG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BESINS MANUFACTURING BELGIUM;REEL/FRAME:027267/0358

Effective date: 20111010

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION